RE:RE:Theralase Releases Results24% is 5% better than Keytruda achieved at 360 days and that was good enough for FDA approval, despite 8% serious side effects and multiple treatments. Plus, the FDA knows 12 of the first 25 TLD1433 patients were undertreated so the ultimate 450 day CR results will be higher as more and more patients receive the optimized treatment. In my opinion Theralase will receive accelerated approval in early 2023, just as Theralase projected in the tumeline.
riverrrow wrote: 24% CR at 450 days for a 2x treatment application with very little side effects seems pretty good to me. I suspect some tweaking of the procedure could bring up the CR. GLTA.